Get the latest Venture Capital & Angel investors news and info Join Our Mailing List:

Your Name: 

Your Email:  

*By submitting your name & email you agree to receive for FREE our scholarships & offers Newsletters. You agree also with the storage and handling of your data by this website and 3rd party email services.
You may unsubscribe if you wish. And you can delete your email and name at any time by emailing us to the email on the bottom of this page.

Follow us on
 
  • Xanthus Secures $25 Million to Advance Development of Its Pipeline

    December 5th, 2006 No comments

    Xanthus Pharmaceuticals, Inc., a privately held oncology drug development company, recently announced that it closed an equity financing, raising $25 Million through the sale of additional shares of its Series B Convertible Preferred Stock. Xanthus’ existing investors were the sole participants in this round including, Oxford Bioscience Partners, HealthCare Ventures, GeneChem, GIMV, Hambrecht & Quist Capital Management, Still River Fund, Neomed, Kestrel Ventures, CDP Capital, CDIB BioScience Ventures, and Yasuda. This brings the total venture capital raised by the company to $88 million.

    “We are pleased to have the continued confidence and support of our high caliber investment team, including our international investors, in this round of funding,” stated Richard T. Dean, Ph.D., Xanthus’ Chief Executive Officer. “With this financing, we believe Xanthus is well-positioned for the continued development of our pipeline of five oncology products.”

    “We believe that the value potential of Xanthus’ pipeline is illustrated by the company’s two low-risk near-term programs and two earlier-stage large-market programs,” stated Mark Carthy of Oxford Bioscience Partners.

    “Xanthus has demonstrated the capability to build a leading oncology franchise and advance an impressive pipeline of product candidates by leveraging its management’s expertise and experience,” stated Christopher K. Mirabelli of HealthCare Ventures. “This team has successfully brought-in additional compounds that we believe will allow Xanthus to capture value in its niche product markets.”

    Xanthus Pharmaceuticals, Inc. is developing a portfolio of novel, clinical-stage, small-molecule oncology candidates through a management team whose accomplished track record encompasses all aspects of drug development, from discovery through regulatory approval and commercialization. The Company is applying its expertise both to advance its current pipeline and expand it into indications of unmet medical need beyond oncology.

    For more information, please visit www.xanthus.com

Leave a reply

Please leave these two fields as-is:

Protected by Invisible Defender. Showed 403 to 252,689 bad guys.

 

Latest Headlines:

Friday August 31, 2012
Zscaler Secures $38 Million Investment Round


Wednesday November 30, 2011
Health Care Solutions companies Infinity Pharmaceutics, NanoVobronix and Selventa raise funds.


Monday November 21, 2011
Panda Power opens $420 Million Fund for Solar and Natural Gas Projects


Thursday November 17, 2011
Better Place raises $200 Million for Electric Cars in the Series C of Funding


Wednesday November 16, 2011
Accel Partners raise $100 Million Big Data Fund to Invest in Hadoop, NoSQL and other Companies


Tuesday November 15, 2011
Skimlinks raises $4.5 Million to help Bloggers Increase their Gains


Monday November 14, 2011
Standing Cloud raises $3 Million to help New Cloud Providers grow Faster


Thursday November 10, 2011
Zillow acquires Diverse Solutions for $7.8 to help Real Estate Agents increase their Visibility


 

By using this website you agree with our cookie policy